So during this EBMT in Madrid, I have the pleasure to present the results of the ARES pivotal study evaluating MaaT013, a new microbiotherapy during the presidential symposium. So this phase three pivotal study shows a high response rate being 62% overall response rate at day 28 for GI graft versus host disease. This is a truly impressive result because this study addressed the unmet need of GI graft versus host disease that fail steroids but also ruxolitinib...
So during this EBMT in Madrid, I have the pleasure to present the results of the ARES pivotal study evaluating MaaT013, a new microbiotherapy during the presidential symposium. So this phase three pivotal study shows a high response rate being 62% overall response rate at day 28 for GI graft versus host disease. This is a truly impressive result because this study addressed the unmet need of GI graft versus host disease that fail steroids but also ruxolitinib. So it was a third-line treatment and we achieved this 62% overall response rate. Most importantly, the response rate was sustained because patients remained in response at day 56 and also at three months, and it translated to a high overall survival for this patient that used to have a very poor and very dismal outcomes.
So when we are going to the treatment of refractory graft-versus-host disease, so steroids is a standard first-line treatment. We have ruxolitinib that is now approved for the second-line treatment of graft-versus-host disease as a patient with GI, skin or liver graft-versus-host disease. For the third-line setting, we don’t have any treatment approved so far. So we have this very exciting result with MaaT013, this microbiotherapy in the third-line setting for patients with GI graft-versus-host disease and we show in the pivotal study the 62% overall response rate at day 28 that truly suggests that it may be the new third-line treatment for those patients to improve their outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
